Follow-up began on the day following the prescription fill and ended with the end of the study, the 25th birthday, loss of enrollment, death, failure to meet study inclusion/exclusion criteria, or 365 days following the last day of current use of the study psychotropic drug.
Follow-up began on the day following the prescription fill and ended with the end of the study, the 25th birthday, loss of enrollment, death, failure to meet study inclusion/exclusion criteria, or 365 days following the last day of current use of a study drug, whichever came first.
This has resulted in low-enrollment heart failure clinical trials, which has been approximated at 0.41 patients per site per month.
We used a structured data extraction tool to describe key data from the eligible studies including: region, study design, primary outcome, data collection dates, enrollment criteria, treatment failure definition, sample size, age range of participants, treatment failure rate, and independent predictors of treatment failure.
Among these patients, the most common reasons allowing enrollment were clinical failure despite prior antibiotic therapy and development of pneumonia while receiving antibacterials for other indications.
Mortality was tracked for 28 days after enrollment, and organ-failure data were based on pediatric-specific criteria [ 19].
Fig. 3 Higher plasma syndecan-1 levels by quartile were associated with non-pulmonary organ dysfunction at enrollment including a circulatory failure, b number of vasopressors, c fluid balance over the first 24 h, d hepatic failure, e renal failure, f coagulation failure.
It is likely, however, that limited enrollment of advanced heart failure patients in the TIMI 11B trial precluded the incorporation of related variables into the final, seven-variable TIMI UA/NSTEMI risk score [2], [23], [25].
Seventy per cent of patients had at least one organ failure at enrollment.
No attempts were made to determine the etiology or management of respiratory failure before enrollment.
